OBJECTIVES: This study was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation. BACKGROUND: Periprocedural management of antiplatelet or anticoagulation therapy at the time of device implantation remains controversial. METHODS: We performed a retrospective chart review of bleeding complications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. Aspirin or clopidogrel use was defined as taken within 5 days of the procedure. A significant bleeding complication was defined as need for pocket exploration or blood transfusion; hematoma requiring pressure dressing or change in anticoagulation therapy; or prolonged hospitalization. RESULTS: Of the 1,388 device implantations, 71 had bleeding complications (5.1%). Compared with controls not taking antiplatelet agents (n = 255), the combination of aspirin and clopidogrel (n = 139) significantly increased bleeding risk (7.2% vs. 1.6%; p = 0.004). In patients taking aspirin alone (n = 536), bleeding risk was marginally higher than it was for patients taking no antiplatelet agents (3.9% vs. 1.6%, p = 0.078). The use of periprocedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258; 14.3% vs. 4.3%; p < 0.001) and compared with patients receiving no anticoagulation therapy (14.3% vs.1.6%; p < 0.0001). There was no statistical difference in bleeding risk between patients continued on warfarin with an INR > or =1.5 (n = 46) and patients who had warfarin withheld until the INR was normal (n = 258; 6.5% vs. 4.3%; p = 0.50). CONCLUSIONS: Dual antiplatelet therapy and periprocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker or ICD implantation. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: This study was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation. BACKGROUND: Periprocedural management of antiplatelet or anticoagulation therapy at the time of device implantation remains controversial. METHODS: We performed a retrospective chart review of bleeding complications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. Aspirin or clopidogrel use was defined as taken within 5 days of the procedure. A significant bleeding complication was defined as need for pocket exploration or blood transfusion; hematoma requiring pressure dressing or change in anticoagulation therapy; or prolonged hospitalization. RESULTS: Of the 1,388 device implantations, 71 had bleeding complications (5.1%). Compared with controls not taking antiplatelet agents (n = 255), the combination of aspirin and clopidogrel (n = 139) significantly increased bleeding risk (7.2% vs. 1.6%; p = 0.004). In patients taking aspirin alone (n = 536), bleeding risk was marginally higher than it was for patients taking no antiplatelet agents (3.9% vs. 1.6%, p = 0.078). The use of periprocedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258; 14.3% vs. 4.3%; p < 0.001) and compared with patients receiving no anticoagulation therapy (14.3% vs.1.6%; p < 0.0001). There was no statistical difference in bleeding risk between patients continued on warfarin with an INR > or =1.5 (n = 46) and patients who had warfarin withheld until the INR was normal (n = 258; 6.5% vs. 4.3%; p = 0.50). CONCLUSIONS: Dual antiplatelet therapy and periprocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker or ICD implantation. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Katarzyna Wiechecka; Bartosz Wiechecki; Agnieszka Kapłon-Cieślicka; Agata Tymińska; Monika Budnik; Dominika Hołowaty; Krzysztof Jakubowski; Marcin Michalak; Elżbieta Świętoń; Przemysław Stolarz; Roman Steckiewicz; Marcin Grabowski; Piotr Scisło; Janusz Kochanowski; Krzysztof J Filipiak; Grzegorz Opolski Journal: Cardiol J Date: 2019-06-21 Impact factor: 2.737
Authors: Mark S Link; Derek V Exner; Mark Anderson; Michael Ackerman; Amin Al-Ahmad; Bradley P Knight; Steven M Markowitz; Elizabeth S Kaufman; David Haines; Samuel J Asirvatham; David J Callans; J Paul Mounsey; Frank Bogun; Sanjiv M Narayan; Andrew D Krahn; Suneet Mittal; Jagmeet Singh; John D Fisher; Sumeet S Chugh Journal: Heart Rhythm Date: 2011-06-14 Impact factor: 6.343
Authors: Samir M Said; Hans D Esperer; Judit Hahn; Andreas Bollmann; Sergio Richter; Thomas Rauwolf; Roland Prondzinsky; Alexander Schmeisser; Ruediger C Braun-Dullaeus Journal: Clin Res Cardiol Date: 2013-02-06 Impact factor: 5.460